The 36-month beta value for MCRB is also noteworthy at 2.53. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for MCRB is 127.46M, and at present, short sellers hold a 13.12% of that float. The average trading volume of MCRB on March 27, 2025 was 1.34M shares.
MCRB) stock’s latest price update
Seres Therapeutics Inc (NASDAQ: MCRB)’s stock price has plunge by 2.05relation to previous closing price of 0.73. Nevertheless, the company has seen a 1.78% surge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-03-13 that Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Carlo Tanzi – Kendall Investor Relations Eric Shaff – President and Chief Executive Officer Lisa von Moltke – Executive Vice President and Chief Medical Officer Matthew Henn – Executive Vice President and Chief Scientific Officer Terri Young – Executive Vice President, Chief Commercial and Strategy Officer Marella Thorell – Executive Vice President and Chief Financial Officer Chris McChalicher – Senior Vice President, Manufacturing, Quality and Process Development Conference Call Participants Joseph Thome – TD Cowen Caroline Pocher – JPMorgan Edward Tenthoff – Piper Sandler John Newman – Canaccord Genuity Operator Thank you for standing by. My name is Kate, and I will be your conference operator today.
MCRB’s Market Performance
MCRB’s stock has risen by 1.78% in the past week, with a monthly drop of -0.69% and a quarterly drop of -22.81%. The volatility ratio for the week is 5.17% while the volatility levels for the last 30 days are 8.36% for Seres Therapeutics Inc The simple moving average for the last 20 days is 2.64% for MCRB stock, with a simple moving average of -13.79% for the last 200 days.
Analysts’ Opinion of MCRB
Oppenheimer, on the other hand, stated in their research note that they expect to see MCRB reach a price target of $12. The rating they have provided for MCRB stocks is “Outperform” according to the report published on June 26th, 2023.
JP Morgan gave a rating of “Neutral” to MCRB, setting the target price at $7 in the report published on April 21st of the previous year.
MCRB Trading at -3.83% from the 50-Day Moving Average
After a stumble in the market that brought MCRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.31% of loss for the given period.
Volatility was left at 8.36%, however, over the last 30 days, the volatility rate increased by 5.17%, as shares surge +4.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.55% lower at present.
During the last 5 trading sessions, MCRB rose by +3.06%, which changed the moving average for the period of 200-days by +22.87% in comparison to the 20-day moving average, which settled at $0.7263. In addition, Seres Therapeutics Inc saw -10.35% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MCRB starting from Young Teresa L., who sale 3,338 shares at the price of $0.81 back on Feb 18 ’25. After this action, Young Teresa L. now owns 97,536 shares of Seres Therapeutics Inc, valued at $2,704 using the latest closing price.
Henn Matthew R., the insider of Seres Therapeutics Inc, sale 3,953 shares at $0.81 during a trade that took place back on Feb 18 ’25, which means that Henn Matthew R. is holding 84,443 shares at $3,204 based on the most recent closing price.
Stock Fundamentals for MCRB
The total capital return value is set at -1.28. Equity return is now at value -3758.21, with -56.05 for asset returns.
Based on Seres Therapeutics Inc (MCRB), the company’s capital structure generated 0.87 points at debt to capital in total, while cash flow to debt ratio is standing at -1.62. The debt to equity ratio resting at 6.65. The interest coverage ratio of the stock is -15.6.
Currently, EBITDA for the company is -121.31 million with net debt to EBITDA at -0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.94.
Conclusion
In summary, Seres Therapeutics Inc (MCRB) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
